English
Specials
    Upgrade
    MoneycontrolBe a PRO
    Moneycontrol PRO
    Upcoming Event:Super25 3.0- India’s Largest Online Stock Traders Conference brought to you by Moneycontrol Pro & Espresso
    you are here: HomeNewsBusinessMoneycontrol Research

    Cipla: Targets for US complex generics on track

    Cipla is looking at launching inhalation product Advair in the second half of FY23

    Anubhav Sahu
    May 12, 2022 / 11:49 AM IST
    Cipla: Targets for US complex generics on track

    PRO Only Highlights
    -      Quarterly performance largely backed by improved realisations
    -      Medium-term triggers China plus and protectionist measures for tyre industry
    -      Valuations not inexpensive; but improved medium-term outlook

    Cipla (CMP: Rs 938; Market Cap: Rs 75,639 crore) has posted a strong top-line growth, backed by both domestic and US businesses. Operational expenses, however, were higher -- partly due to the higher procurement cost and R&D expenses. While some of the cost headwinds in the post-COVID world would stay for a while, a healthy growth in the complex generics and consumer health segments for the company is noticeable. Q4FY22 financials (image) Source: Cipla The March quarter sales were up 14 percent year...

    • PRO Panorama

      Moneycontrol Pro​ Panorama | Auto wreck

      May 12, 2022 / 05:58 PM IST

      In today’s edition of Moneycontrol Pro​ Panorama: Bond yields flashing red, Sri Lankan crisis decoded, Jinping eyes third term, Start-Up Street and more

      Read Now
    • PRO Weekender

      Moneycontrol Pro Weekender | Losing faith

      May 7, 2022 / 10:05 AM IST

      Central banks have a trust problem with financial markets over their ability to steer economies towards a soft landing

      Read Now

    To read the full story, Subscribe to Moneycontrol PRO

    Access the exclusive stories, weekly investment ideas and daily technical calls in an Ad free experience

    View Plans

    Already a member? Sign in

    Limited Period offer on Moneycontrol PRO. Subscribe to PRO and get up to

    50% OFF

    What Do You Get

    • Ad free experience

      Experience a non-intrusive navigation and faster response in the ad free mode

    • Sharpest Opinions

      Access to 230+ exclusive stories per month from our editorial and Experts

    • +

      Have a Global edge with access to content from world renowned experts and journalist

    • Actionable Insights

      Access to 40+ weekly investment ideas including 4 daily technical calls

    • Virtual Events

      Exclusive access to live webinars from market experts on trading and investment strategies

    • Newsletters

      Daily and weekly insights bundled and sent to your inbox to keep you ahead in the race.

    View Offers

    Get upto 50% discount on limited period offers